



**HAL**  
open science

## Reply to hep-21-0216 'acute liver injury due to therapeutic doses of acetaminophen - confounders must be ruled out!'

Alexandre Louvet, Philippe Mathurin

### ► To cite this version:

Alexandre Louvet, Philippe Mathurin. Reply to hep-21-0216 'acute liver injury due to therapeutic doses of acetaminophen - confounders must be ruled out!'. *Hepatology (Baltimore, Md.)*, 2021, *Hepatology (Baltimore, Md.)*, 10.1002/hep.31769 . hal-04487990

**HAL Id: hal-04487990**

**<https://hal.univ-lille.fr/hal-04487990v1>**

Submitted on 4 Mar 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Letter to the Editor: Acute Liver Injury Due to Therapeutic Doses of Acetaminophen—Confounders Must Be Ruled Out!

### TO THE EDITOR:

We read the study by Louvet et al.<sup>(1)</sup> describing risk factors and outcomes associated with acute liver injury due to therapeutic doses of acetaminophen (ALITD) with great interest. They conclude that ALITD is associated with severe liver injury and occurs in patients with excess alcohol consumption or fasting. This makes us ponder the mechanisms behind ALITD to prospectively modify host risk factors associated with therapeutic misadventure of acetaminophen. However, certain issues warrant further clarification.

First, it is of paramount importance to rule out underlying chronic liver disease. Patients with cirrhosis have low acetaminophen clearance,<sup>(2)</sup> which may predispose these patients to ALITD. Approximately 60% patients with acute liver failure may have ascites and features of portal hypertension,<sup>(3)</sup> and absence of features of decompensation may be insufficient in ruling out cirrhosis. Apart from cirrhosis, patients with NASH have up-regulated cytochrome P450 2E1 (CYP2E1)<sup>(4)</sup> and reduced intrahepatic glutathione,<sup>(5)</sup> predisposing them to acetaminophen-induced liver injury. It would be of interest to know how many patients had NASH and whether metabolic risk factors were associated with an increased risk of developing ALITD.


Second, the duration of alcohol intake is as important as the amount of alcohol consumed. Patients with chronic alcohol abuse may have significant hepatic fibrosis, which may predispose them to ALITD. Third, an important aspect of acetaminophen toxicity is formation of N-acetyl-p-benzoquinone imine through CYP2E1, and it is pertinent to know whether patients with ALITD were on any drugs that compete with hepatic glucuronidation or induce CYP2E1 that can lead to increased acetaminophen toxicity. Last, the researchers conclude that ALITD is associated with severe disease in comparison to acetaminophen overdose. However, on multivariate analysis, ALITD was

neither associated with increased mortality nor presence of at least one of the King's College Hospital criteria. Although more patients in ALITD were fasting, its effect was also not adjusted for in multivariate analysis.

In conclusion, the study provides new insight about ALITD; however, clinicians should also pay heed to presence of metabolic risk factors, fatty liver, and concurrent drug use while prescribing acetaminophen.

*Author Contributions:* N.V.: writing; R.M.: writing and critical revision; V.S.: writing and critical revision.

Nikhil Vojjala, M.B.B.S.<sup>1</sup>

Rohit Mehtani, M.D. <sup>2</sup>

Virendra Singh, D.M. <sup>2</sup>

<sup>1</sup>Department of Internal Medicine

Post Graduate Institute of Medical Education and Research, Chandigarh, India

<sup>2</sup>Department of Hepatology

Post Graduate Institute of Medical Education and Research, Chandigarh, India

### REFERENCES

1. Louvet A, Ntandja Wandji LC, Lemaître E, Khaldi M, Lafforgue C, Artru F, et al. Acute liver injury with therapeutic doses of acetaminophen: a prospective study. *HEPATOLOGY* 2021;74:1945-1955.
2. Zapater P, Lasso de la Vega MC, Horga JF, Such J, Frances R, Esteban A, et al. Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. *Aliment Pharmacol Ther* 2004;20:29-36.
3. Navasa M, Garcia-Pagán JC, Bosch J, Riera JR, Banares R, Mas A, et al. Portal hypertension in acute liver failure. *Gut* 1992;33:965-968.
4. Chtioui H, Semela D, Ledermann M, Zimmermann A, Dufour JF. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. *Liver Int* 2007;27:764-771.
5. Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quiñones L, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. *Clin Sci* 2004;106:261-268.

© 2021 by the American Association for the Study of Liver Diseases.

View this article online at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).

DOI 10.1002/hep.31774

Potential conflict of interest: Nothing to report.

### REPLY:

We disagree with the conclusion of Vojjala et al., which states that clinicians should pay attention to

metabolic risk factors, fatty liver, and concurrent drug use.

The authors questioned the presence of NAFLD in our study. However, the median body mass index

(BMI) was normal in the patients admitted with acute liver injury due to therapeutic doses (ALITD) and was not different from that of patients admitted with acetaminophen overdose: 21.9 versus 22 kg/m<sup>2</sup>,  $P = 0.5$ . Therefore, the prevalence of metabolic syndrome was a rare event. Moreover, previous studies have not identified any relationship between BMI and the outcome or pattern of intoxication.<sup>(1)</sup> Obesity was not found to have any impact on acetaminophen toxicity in the study by Radosevich et al.<sup>(2)</sup>

In relation to drug–drug interactions, none of the published clinical studies evaluating acetaminophen toxicity has found drug intake to be an aggravating factor. The median age in our study was 35 years, making chronic drug intake a rare event, which was therefore not assessed. Interestingly, a review concluded that the use of drugs concurrent with a paracetamol overdose should not be considered a risk factor of hepatotoxicity.<sup>(3)</sup>

Our study acknowledged that fasting can be a precipitating factor, although it was not powered to address its impact on outcome. Nevertheless, the patients who had fasted before admission had the same 30-day survival as the others, 95.3% versus 95.7%,  $P = 0.9$ ; and fasting was not associated with disease severity ( $P = 0.2$ ). Thus, fasting seems to be more a precipitating factor of ALITD than a driver of outcome, compared to excessive alcohol consumption.

Vojjala et al. also question the presence of cirrhosis in our patients with ALITD. We disagree that cirrhosis was a confounding factor because we excluded the 7 patients with cirrhosis. In addition, when looking at the evolution of patients with ALITD, a factor V and a prothrombin rate parallel to those of patients with overdose would not have been observed if cirrhosis were present. Although we cannot exclude the presence of fibrosis, extensive fibrosis can be excluded based on the biological kinetics.

Finally, the authors' interpretation of ALITD in multivariate analysis is questionable. In fact, ALITD and excessive drinking are closely connected. Thus, in a multivariate analysis of overall patients, this close relationship results in nonsignificance, especially because alcohol is an aggravating factor in overdose.

In summary, we agree that additional data will help further understand acetaminophen toxicity, either from therapeutic doses or from overdose. Conversely, we believe that these future results can only be obtained from an evidence-based approach that can help drive expert opinion.

Alexandre Louvet, M.D., Ph.D. <sup>1,2</sup>

Philippe Mathurin, M.D., Ph.D.<sup>1,2</sup>

<sup>1</sup>Service des Maladies de l'appareil digestif  
Hôpital Huriez, Lille, France

<sup>2</sup>Unité INFINITE U1286

Faculté de médecine, Lille, France

## REFERENCES

- 1) Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. *HEPATOLOGY* 2005;42:1364-1372.
- 2) Radosevich JJ, Patanwala AE, Erstad BL. Hepatotoxicity in obese versus nonobese patients with acetaminophen poisoning who are treated with intravenous N-acetylcysteine. *Am J Ther* 2016;23:e714-e719.
- 3) Kalsi SS, Wood DM, Waring WS, Dargan PI. Does cytochrome P450 liver isoenzyme induction increase the risk of liver toxicity after paracetamol overdose? *Open Access Emerg Med* 2011;3:69-76.

© 2021 by the American Association for the Study of Liver Diseases.

View this article online at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).

DOI 10.1002/hep.31769

Potential conflict of interest: Nothing to report.

## Letter to the Editor: Serum Albumin in COVID-19: A Good Example in Which Analytical and Clinical Performance of a Laboratory Test Are Strictly Intertwined

### TO THE EDITOR:

We read with interest the paper by Hundt et al. describing the behavior of common liver tests in

Coronavirus disease 2019 (COVID-19) and their association with poor outcomes.<sup>(1)</sup> Among the presented data, we were surprised to see that serum albumin (ALB) concentrations during hospitalization did not significantly predict patient death at the multivariate